Enhanced Games sells drugs and true cost won’t be known for many years

The inaugural Enhanced Games, set to take place in Las Vegas, introduces a controversial new model of competitive sports where athletes are allowed to use performance-enhancing drugs under medical supervision. The event promotes itself as a celebration of human potential through “safe, transparent enhancement,” offering substantial financial rewards including $1 million for breaking world records and $250,000 for race wins. Notable athletes such as American sprinter Fred Kerley and British swimmer Ben Proud are participating, with the latter having undergone a specialized training camp in Abu Dhabi where enhancement drugs were tailored to individual needs. Unlike traditional sports governed by anti-doping regulations, the Enhanced Games permit substances like steroids, testosterone, and growth hormone, which are banned by the World Anti-Doping Agency (WADA). While the event aims to showcase the potential of medically supervised enhancement, experts warn that the long-term health consequences for athletes remain unknown and could emerge only years later. The competition also serves as a clinical trial, collecting data on drug effects and performance improvements, which organizers plan to use for marketing and commercial purposes. Former Olympic swimmer and pharmaceutical industry veteran Nick O’Hare highlights the commercial motivations behind the Games, describing it as a platform to promote personalized performance medicine and supplements. The data gathered from elite athletes is expected to be leveraged to attract recreational users, potentially expanding the market for enhancement drugs. This raises ethical concerns about the exploitation of athletes as test subjects and the broader implications for sports integrity and public health. The Enhanced Games thus represent a significant departure from conventional sports, blending competition with pharmaceutical experimentation and commercialization. While offering unprecedented financial incentives and pushing the boundaries of human performance, the event also ignites debate over the safety, fairness, and future of athletic competition in an era of drug-enhanced capabilities.